Dow Corning adds $400 mil. in implant liability funds from insurers with Feb. 14 verdict.
This article was originally published in The Gray Sheet
Executive Summary
DOW CORNING BREAST IMPLANT LIABILITY INSURANCE COVERAGE GROWS TO $945 MIL. for existing claims following a Feb. 14 jury verdict holding insurance companies liable for about $400 mil. in coverage. Dow Corning already has reached tentative settlements with other insurers for an additional $545 mil. to cover current plaintiff claims as well as $630 mil. for potential future claims.You may also be interested in...
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: